ABIVAX Société Anonyme (NASDAQ:ABVX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of ABIVAX Société Anonyme (NASDAQ:ABVX) have been given an average rating of “Moderate Buy” by the five research firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $39.80.

Separately, JMP Securities initiated coverage on ABIVAX Société Anonyme in a research note on Wednesday. They issued an “outperform” rating and a $33.00 target price on the stock.

ABIVAX Société Anonyme Stock Performance

Shares of ABVX opened at $8.30 on Wednesday. The business’s fifty day moving average price is $9.95 and its 200 day moving average price is $11.67. ABIVAX Société Anonyme has a 12-month low of $8.06 and a 12-month high of $17.02.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. abrdn plc grew its holdings in ABIVAX Société Anonyme by 167.7% during the third quarter. abrdn plc now owns 316,431 shares of the company’s stock worth $3,645,000 after acquiring an additional 198,225 shares during the period. BNP Paribas Financial Markets grew its holdings in ABIVAX Société Anonyme by 82.6% during the third quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock worth $150,000 after acquiring an additional 5,900 shares during the period. Walleye Capital LLC grew its holdings in ABIVAX Société Anonyme by 45.8% during the third quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock worth $2,965,000 after acquiring an additional 80,807 shares during the period. Finally, Point72 Asset Management L.P. grew its holdings in ABIVAX Société Anonyme by 28.2% during the third quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company’s stock worth $6,254,000 after acquiring an additional 119,300 shares during the period. 47.91% of the stock is owned by institutional investors and hedge funds.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.